Skip to content

SAR441566

DRUG11 trials

Sponsors

Sanofi-Aventis Recherche & Developpement, Sanofi

Conditions

Colitis UlcerativeCrohn's DiseaseCrohn's diseasePsoriasisRheumatoid ArthritisRheumatoid arthritis

Phase 1

Phase 2

A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis
CompletedNCT06073093
SanofiRheumatoid Arthritis
Start: 2023-11-07End: 2025-07-02Updated: 2025-07-11
A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis
CompletedNCT06073119
SanofiPsoriasis
Start: 2023-10-26End: 2024-12-11Updated: 2025-11-10
A Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging study of Efficacy and Safety of SAR441566 in Adults with Moderate to Severe Plaque Psoriasis
CompletedCTIS2023-503911-14-00
Sanofi-Aventis Recherche & DeveloppementPsoriasis
Start: 2024-01-25End: 2024-11-20Target: 242Updated: 2024-12-09
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety study of SAR441566 plus Methotrexate in Adults with Moderate to Severe Rheumatoid Arthritis
CompletedCTIS2023-503910-60-00
Sanofi-Aventis Recherche & DeveloppementRheumatoid arthritis
Start: 2024-03-05End: 2025-07-02Target: 194Updated: 2025-08-19
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
Active, not recruitingNCT06637631
SanofiCrohn's Disease
Start: 2024-12-10End: 2026-10-14Target: 260Updated: 2026-09-11
A Phase 2, multinational, multicenter, randomized, double blind, placebo controlled, dose-ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate to severe Crohn’s disease.
RecruitingCTIS2024-512633-32-00
Sanofi-Aventis Recherche & DeveloppementCrohn's disease
Start: 2025-04-07Target: 169Updated: 2026-01-09
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
Active, not recruitingNCT06867094
SanofiColitis Ulcerative
Start: 2025-03-28End: 2026-10-14Target: 204Updated: 2026-09-11
A Phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate-to-severe ulcerative colitis
RecruitingCTIS2025-520705-12-00
Sanofi-Aventis Recherche & DeveloppementColitis Ulcerative
Start: 2025-06-24Target: 150Updated: 2025-12-03